Biocius Buy Key to Agilent's Clinical Proteomics Plans

While Biocius' RapidFire technology has traditionally been used by pharma firms for drug-screening work, "one of the key opportunities" Agilent sees is applying the platform "to the clinical proteomics space," a company official said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.